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ABSTRACT
Background Evidence about the impact of systematic 
nursing surveillance on risk of acute deterioration of 
patients with COVID-19 and the effects of care complexity 
factors on inpatient outcomes is scarce. The aim of 
this study was to determine the association between 
acute deterioration risk, care complexity factors and 
unfavourable outcomes in hospitalised patients with 
COVID-19.
Methods A multicentre cohort study was conducted 
from 1 to 31 March 2020 at seven hospitals in Catalonia. 
All adult patients with COVID-19 admitted to hospitals 
and with a complete minimum data set were recruited 
retrospectively. Patients were classified based on the 
presence or absence of a composite unfavourable 
outcome (in- hospital mortality and adverse events). The 
main measures included risk of acute deterioration (as 
measured using the VIDA early warning system) and care 
complexity factors. All data were obtained blinded from 
electronic health records. Multivariate logistic analysis 
was performed to identify the VIDA score and complexity 
factors associated with unfavourable outcomes.
Results Out of a total of 1176 patients with COVID-19, 
506 (43%) experienced an unfavourable outcome during 
hospitalisation. The frequency of unfavourable outcomes 
rose with increasing risk of acute deterioration as 
measured by the VIDA score. Risk factors independently 
associated with unfavourable outcomes were chronic 
underlying disease (OR: 1.90, 95% CI 1.32 to 2.72; 
p<0.001), mental status impairment (OR: 2.31, 95% CI 
1.45 to 23.66; p<0.001), length of hospital stay (OR: 1.16, 
95% CI 1.11 to 1.21; p<0.001) and high risk of acute 
deterioration (OR: 4.32, 95% CI 2.83 to 6.60; p<0.001). 
High- tech hospital admission was a protective factor 
against unfavourable outcomes (OR: 0.57, 95% CI 0.36 to 
0.89; p=0.01).
Conclusion The systematic nursing surveillance of the 
status and evolution of COVID-19 inpatients, including the 
careful monitoring of acute deterioration risk and care 
complexity factors, may help reduce deleterious health 
outcomes in COVID-19 inpatients.
INTRODUCTION
Along with climate change and financial 
crises, pandemics are a major global risk in 
the 21st century. A 2019 report stated that, 
in the last decade, the WHO had tracked 
1483 epidemic events, including severe 
acute respiratory syndrome (SARS), Middle 
East respiratory syndrome, Ebola and other 
epidemic- prone diseases, considered harbin-
gers of a new era of high- impact, potentially 
fast- spreading outbreaks.1
The potential threat became real in 
December 2019, when a severe acute respira-
tory infection caused by the new coronavirus 
SARS- CoV-2 first began to spread in Wuhan 
(China).2 3 The WHO described the ‘Wuhan 
pneumonia’ as an outbreak of potential 
danger on 31 December, and as an outbreak 
of global concern on 31 January. This corona-
virus disease (named COVID-19) was declared 
a global pandemic in February 2020.
Strengths and limitations of this study
 ► We performed a multicentre cohort study with a 
large sample of patients with COVID-19.
 ► This novel research assessed the impact of the 
risk of acute deterioration and broader contributors 
to care complexity on outcomes of patients with 
COVID-19.
 ► We did not evaluate other clinical measures such as 
the age- adjusted Charlson Comorbidity Index or pa-
tient laboratory values.
 ► The results of this study only apply to adult wards 
and intermediate care inpatients.
 ► The risk of acute deterioration was measured using 
VIDA, an early warning system not yet fully imple-
mented in all hospital wards.
P
rotected by copyright.












pen: first published as 10.1136/bm





2 Adamuz J, et al. BMJ Open 2021;11:e041726. doi:10.1136/bmjopen-2020-041726
Open access 
Patients with COVID-19 frequently require hospital 
admission as they may rapidly develop severe potentially 
life- threatening complications, such as acute respiratory 
distress syndrome (ARDS), sepsis, major thromboem-
bolic events or cardiac injury, requiring intensive care.3–5 
Recent studies have found overall in- hospital mortality 
rates for COVID-19 inpatients ranging from 15% to 
28%.3 6–8 Therefore, early recognition of patient deteri-
oration and escalation of treatment to reduce the risk of 
progression to critical complications is a significant issue 
that may impact patient and organisational outcomes. 
Screening for acute deterioration implies nursing surveil-
lance, data collection, interpretation and recognition of 
changes in patients’ status, prioritisation of patients’ prob-
lems and decision- making on the interventions needed in 
order to curb the cascade towards adverse events (AEs) 
and death.9
According to the WHO, ‘patients hospitalized with 
COVID-19 require regular monitoring of vital signs and, where 
possible, utilization of early warning scores that facilitate early 
recognition and escalation of treatment of the deteriorating 
patient.’10 Early warning systems have become an important 
component of managing inpatient care, and are a clinical 
decision- making support stratification tool used to prevent 
poor health outcomes.11–13 Previous studies suggested the 
need for adaptation of these systems to each context.14 
According to these recommendations, several evidence- 
based algorithms have been developed and used to identify 
and act on initial or impending acute deterioration among 
hospitalised patients in a timely fashion. In the context of 
this study, a nursing surveillance improvement programme 
named VIDA (the Catalan acronym for Surveillance and 
Identification of Acute Deterioration) was first imple-
mented in 2013 and, through a multidisciplinary approach, 
has evolved into an early warning score system that is used 
on a daily basis to assist clinical decision- making.
It has been reported that patients hospitalised with 
COVID-19 have a substantial rate of chronic conditions 
that may affect the complexity of medical and nursing 
care provision and patient health outcomes.15 Never-
theless, care complexity individual factors (CCIF) are 
related to multiple comorbidities and mental- cognitive 
and psychosocial patient features, which in turn are also 
associated with increased healthcare needs during hospi-
talisation and with selected health outcomes.16–18
Only a few studies in COVID-19 inpatients have explored 
the use of acute deterioration risk stratification11 19 and to 
date, none has assessed CCIF as predictors of poor health 
outcomes. The aim of this study was to determine the 
association between the risk of acute deterioration (as 
measured using the VIDA early warning system), CCIF 
and unfavourable outcomes in patients hospitalised with 
COVID-19.
METHODS
Setting and study design
A retrospective cohort study was carried out at seven public 
hospitals in Catalonia, Spain: three tertiary metropolitan 
facilities, three urban university centres and one commu-
nity hospital. All patients with a medical diagnosis of 
COVID-19 infection admitted to a ward or intermediate 
unit for COVID-19 or other causes from 1 to 31 March 
2020 with a completed hospital minimum data set report 
were recruited retrospectively and followed up during 
hospitalisation until discharge or death. Patients directly 
admitted and discharged from intensive care units (ICU) 
were excluded because the VIDA early warning system is 
not used in the ICU. Patients who remained hospitalised 
after the recruitment end date were also excluded as the 
hospital minimum data set was not available.
We defined the primary endpoint as a composite of 
unfavourable outcomes including in- hospital mortality or 
AEs, not present on admission and occurring thereafter 
during hospitalisation.
Patient and public involvement
Patients were not involved in the design, conduct or 
reporting of this study.
Data collection
Information regarding the demographic and clinical 
characteristics, continuity of care (discharged to another 
facility), high- tech hospital (referral centre that provides 
tertiary care for either open- heart surgery or major organ 
transplants or both), length of hospital stay (LOS) and 
patient severity and mortality risk was collected from the 
hospital minimum data set and the clinical data ware-
house of the Catalan Institute of Health. Patient severity 
and risk of mortality were based on the All Patient 
Refined Diagnosis- Related Group (APR- DRG), which 
categorises both measures from low (level 1) to extreme 
(level 4). Severity and mortality risk were dichotomised in 
this study into low risk (levels 1–2) and high risk (levels 
3–4).20 All variables were collected during hospitalisation.
The VIDA score (acute deterioration risk stratification) 
automatically classifies patients into five groups according 
to patient progress data: no risk (level 0), low risk (level 
1), moderate risk (level 2), high risk (impending compli-
cation if not stabilised) (level 3), manifested complication 
initial status (level 4). Levels 2–4 create an alert in the 
electronic health records and require action in response 
to clinical recommendations. These recommendations 
are standardised for each context and involve intensifying 
the surveillance of the patients’ status and notifying the 
medical team. The health team (nurse and specialist) are 
responsible for the final clinical decision- making. For the 
purposes of this study, the VIDA score was classified as 
mild (levels 1–2) or high (levels 3–4) risk. Patients were 
classified according to the highest VIDA score obtained 
during their hospitalisation. Patient progress data were 
extracted from anonymised electronic health records 
whenever they were e- charted, and included: respira-
tory rate (breaths per minute), oxygen saturation (%), 
temperature (°C), mental status (level of awareness: 
1=aware and orientated, >1=disturbed mental status, 
including disorientation, acute confusion, and so on), 
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pulse (cardiac rate, beats per minute) and systolic and 
diastolic blood pressure (mm Hg) (online supplemental 
file 1).
CCIFs were classified into five domains: (1) mental- 
cognitive, (2) psychoemotional, (3) sociocultural, (4) 
developmental, and (5) comorbidity/complications, as 
described in previous studies.16 18 Each CCIF domain 
is structured into factors and specifications. Patients 
were considered to fall within any CCIF domains if they 
presented at least one factor or specification during their 
hospitalisation. These CCIF factors and specifications 
were obtained from the nursing assessment e- charts as 
structured data based on the Architecture, Terminology, 
Interface, Knowledge terminology20 (online supple-
mental file 2).
Outcome measures
The main endpoint was a composite of unfavourable 
outcomes including in- hospital mortality and AEs during 
hospitalisation. The in- hospital mortality counted the 
number of patients with COVID-19 dying while in a ward. 
The AEs included ICU transfer, hospital- acquired infec-
tions (HAI) and potentially avoidable critical compli-
cations (ACC) during hospitalisation. ICU transfer was 
defined as the number of patient episodes with effective 
bed change from a general ward to an intensive care area. 
HAI included the number of episodes of ward patients 
who developed catheter- related bloodstream infection, 
urinary catheter- related infection, aspiration pneumonia 
and/or sepsis. ACC accounted for the number of episodes 
of ward patients who experienced a cardiac arrest, shock, 
thromboembolic event, acute respiratory failure, ARDS, 
myocardial injury, liver injury and/or kidney failure, not 
present on admission.
Statistical analysis
Descriptive analysis of data using percentage frequencies, 
median and IQR was performed to determine demo-
graphic and clinical characteristics and patient outcomes. 
For categorical variables, a comparative analysis for 
detecting significant differences between groups was 
carried out using the χ2 test or Fisher’s exact test when 
one or more cells had an expected frequency of 5 or less. 
For continuous variables, the Student’s t- test or Mann- 
Whitney U test was used depending on the results of the 
Kolmogorov- Smirnov normality test. A logistic regression 
model of all clinical factors potentially associated with 
unfavourable outcome measures (AEs and in- hospital 
mortality) was performed including the VIDA score, clini-
cally relevant CCIF and other potential confounders: sex, 
hospital level and LOS. All potential explanatory vari-
ables included in the multivariate analysis were subjected 
to a correlation matrix for analysis of collinearity. The 
discriminatory power was evaluated by the area under 
the receiver operating characteristic curve (AUC). The 
results of the multivariate analysis were reported as OR 
and 95% CIs. We also performed an adjusted analysis to 
compare unfavourable outcomes in patients admitted 
to wards with and without the VIDA system. Statistical 
analysis was performed using the SPSS software package 
V.25.0 (SPSS). P values <0.05 were considered statistically 
significant.
RESULTS
During the study period, 1838 patients were hospitalised 
with COVID-19, of which 1176 met the inclusion criteria 
(figure 1). The frequency of unfavourable outcomes was 
42.8% (506 patients). The in- hospital mortality rate was 
19.6% (232 patients), and almost 41% (481 patients) 
experienced an AE while in a ward (2.7% transferred 
to ICU; 2.5% HAI; 40% ACC). Acute respiratory failure, 
ARDS, acute kidney failure, urinary catheter- related 
infection, sepsis and thrombotic events were the most 
frequent AEs.
Patient characteristics
The baseline characteristics of patients with an unfavour-
able and favourable outcome are compared in table 1. 
Hospitalised patients with COVID-19 who had an unfa-
vourable outcome were more often male, older and had 
one or more underlying chronic conditions (75.5%), 
mostly arterial hypertension or congestive heart failure, 
and diabetes or chronic kidney disease. Furthermore, 
they had a longer LOS and a high risk of severity or 
mortality (APR- DRG 3–4). Conversely, patients admitted 
to high- tech hospitals presented a lower frequency of 
unfavourable outcomes.
Among the 806 patients in wards where the VIDA early 
warning system was in use, most patients with unfavour-
able outcomes experienced a high risk of acute deterio-
ration (41.7% in patients with unfavourable outcomes vs 
9.1% in patients with favourable outcomes).
Comorbidity, sociocultural and developmental domains 
were the most frequent CCIF domains identified in the 
studied sample. Mental- cognitive and psychoemotional 
domains were less frequent. Patients with unfavour-
able outcomes exhibited a higher frequency of chronic 
disease, position impairment, anatomical and functional 
disorders, communication disorders, old age (>75 years) 
and mental status impairment, when compared with 
patients with favourable outcomes. The median CCIF was 
also higher in patients with unfavourable outcomes (5 
[IQR: 4–6] vs 4 [IQR: 3–5]) (table 1).
Association of outcomes with risk of acute deterioration and 
care complexity factors
The outcomes of 806 patients with low, mild or high 
risk of acute deterioration are compared in table 2. The 
frequency of unfavourable outcomes was almost 38% in 
patients with mild risk and almost 80% in those at high risk 
of acute deterioration (p<0.001). Similarly, the frequency 
of in- hospital mortality and AEs rose with increasing 
VIDA score and was around 60% and 80%, respectively, in 
patients with a high risk of acute deterioration (p<0.001). 
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Acute respiratory failure, acute kidney failure and ICU 
transfer were the most frequent AEs.
Among the 1176 patients analysed in this study, those 
with four or more CCIFs experienced unfavourable 
outcomes (p<0.05) (table 2).
Table 3 shows an adjusted analysis of health outcomes 
in 486 patients with a high risk of mortality (APR- DRG 
3–4). In- hospital mortality was more frequent in patients 
admitted to wards where VIDA was not used (52.5% vs 
41.3%, p<0.05). Conversely, the frequency of AEs was 
slightly higher in patients admitted to wards using VIDA 
(p<0.05).
Risk factors associated with unfavourable outcomes
The results of the multivariate analysis for risk of acute 
deterioration (as measured using the VIDA score) and 
CCIF potentially associated with unfavourable outcomes, 
in- hospital mortality and AEs are summarised in table 4.
After adjustment for potential confounders, the analysis 
showed that a high risk of acute deterioration was an inde-
pendent factor associated with unfavourable outcomes, 
in- hospital mortality and AEs in COVID-19 inpatients. 
Furthermore, chronic disease, mental status impairment 
and LOS were risk factors associated with unfavourable 
outcomes. Conversely, high- tech hospital admission was 
a protective factor against unfavourable outcomes. The 
AUC was 0.81 (95% CI 0.78 to 0.84).
Chronic disease, mental status impairment, old age and 
male sex were independent risk factors associated with 
in- hospital mortality in the studied COVID-19 inpatients 
(AUC 0.91, 95% CI 0.88 to 0.93). Finally, risk factors 
independently associated with AEs were chronic disease, 
mental status impairment, old age and LOS, whereas 
high- tech hospital admission was a protective factor 
against AEs (AUC 0.80, 95% CI 0.77 to 0.83). The AUCs 
of the three outcomes analysed were >0.80, showing a fair 
discriminatory power.
DISCUSSION
In this study of a large cohort of hospitalised patients with 
COVID-19, the frequency of in- hospital mortality and 
AEs was around 60% and 80%, respectively, in patients 
scored as at high risk of acute deterioration. In- hospital 
mortality was higher in wards not using the VIDA early 
warning system. The majority of patients had four or 
more care complexity factors identified. The risk factors 
independently associated with unfavourable outcomes 
included chronic disease, mental status impairment, LOS 
and a high risk of acute deterioration. High- tech hospital 
admission was a protective factor against unfavourable 
outcomes.
Our findings are consistent with previous COVID-19 
reports that found a similar frequency of in- hospital 
mortality and AEs.3 21 In addition, 37% of patients devel-
oped respiratory complications (acute respiratory failure 
or ARDS) during hospitalisation. This value is within the 
range reported in a previous study (29%–42%).3
Figure 1 Flow chart of patient selection process. APR- DRG, All Patient Refined Diagnosis- Related Group; VIDA, Surveillance 
and Identification of Acute Deterioration.
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P valuen (%) n (%) n (%)
Demographic characteristics
  Age (years), median (IQR) 66.5 (51–77) 74 (60–80) 61 (49–74) <0.001
  Male sex 667 (56.7) 192 (37.9) 317 (47.3) 0.001
Clinical characteristics
  LOS, median (IQR) 6 (4–8) 7 (4–10) 5 (4–7) <0.001
  Continuity of care (discharged to another facility) 165 (14) 58 (11.5) 107 (16) 0.02
  Severity (APR- DRG 3–4) 503 (42.8) 450 (88.9) 53 (7.9) <0.001
  Mortality risk (APR- DRG 3–4) 486 (41.3) 449 (88.7) 37 (5.5) <0.001
  High- tech hospital 969 (82.4) 389 (76.9) 580 (86.6) <0.001
  Underlying disease 745 (63.4) 382 (75.5) 363 (54.4) <0.001
   Arterial hypertension or chronic heart failure 469 (39.9) 234 (46.2) 235 (35.1) <0.001
   Diabetes or chronic kidney disease 298 (25.3) 165 (32.6) 133 (19.9) <0.001
   Chronic respiratory disease 171 (14.5) 95 (18.8) 76 (11.3) <0.001
   Neurodegenerative disease 63 (5.3) 33 (6.5) 39 (4.5) 0.15
   Chronic liver disease 54 (4.6) 30 (5.9) 24 (3.6) 0.07
   Cancer 50 (4.3) 31 (6.5) 19 (2.8) 0.008
   Immunosuppression 49 (4.2) 23 (4.5) 26 (3.9) 0.66
VIDA score†
  Low risk (0) 104 (12.9) 27 (7.1) 77 (18) <0.001
  Moderate risk (1–2) 505 (62.7) 194 (51.2) 311 (72.8) <0.001
  High risk (3–4) 197 (16.7) 158 (41.7) 39 (9.1) <0.001
Care complexity individual factors (CCIF)
  Comorbidity/complications 1176 (100) 506 (9.1) 670 (100) –
   Transmissible infection 1176 (100) 506 (100) 670 (100) –
   Haemodynamic instability 910 (77.4) 396 (78.3) 514 (76.7) 0.57
   Chronic disease 745 (63.4) 382 (75.5) 363 (54.4) <0.001
   Uncontrolled pain 194 (16.5) 82 (16.2) 112 (16.7) 0.87
   Extreme weight 168 (14.3) 82 (16.2) 86 (12.8) 0.11
   Position impairment 72 (6.1) 52 (10.3) 20 (3.0) <0.001
   Urinary or faecal incontinence 58 (4.9) 31 (6.1) 27 (4.0) 0.10
   Immunosuppression 49 (4.1)
   Anatomical and functional disorders 41 (3.5) 30 (5.9) 11 (1.6) <0.001
   Communication disorders 18 (1.5) 13 (2.6) 5 (0.7) 0.01
   High risk of haemorrhage 2 (0.2) 1 (0.2) 1 (0.1) 0.68
   Vascular fragility 6 (0.5) 4 (0.8) 2 (0.3) 0.41
   Involuntary movements 3 (0.3) 3 (0.6) 0 (0.0) 0.08
   Dehydration 3 (0.3) 1 (0.2) 2 (0.3) 0.60
   Oedema 0 (0) 0 (0.0) 0 (0.0) –
  Developmental 397 (33.8) 244 (48.2) 153 (22.8) <0.001
   Old age (≥75 years) 397 (33.8) 244 (48.2) 153 (22.8) <0.001
  Psychoemotional 218 (18.5) 86 (17.0) 132 (19.7) 0.13
   Fear/anxiety 173 (14.7) 70 (13.8) 103 (15.4) 0.51
   Impaired adaptation 54 (4.6) 17 (3.4) 37 (5.5) 0.09
   Aggressive behaviour 1 (0.1) 1 (0.2) 0 (0.0) 0.43
  Mental- cognitive 240 (20.4) 184 (36.4) 56 (8.4) <0.001
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The results of this study show that a high risk of acute 
deterioration is a significant risk factor for unfavour-
able outcomes, as a composite measure for in- hospital 
mortality and AEs in COVID-19 inpatients. Although 
previous studies have stressed that early warning systems 
are predictors of in- hospital mortality and health 
outcomes,22 23 only a few have evaluated warning score 
systems in COVID-19 inpatients.11 19 These latest studies 
showed a fair discrimination with adverse outcomes, illus-
trating that evaluating the risk for acute deterioration in 









P valuen (%) n (%) n (%)
   Agitation 5 (0.4) 4 (0.8) 1 (0.1) 0.17
   Impaired cognitive functions 4 (0.3) 3 (0.6) 1 (0.1) 0.32
   Perception of reality disorders 2 (0.2) 0 (0.0) 2 (0.3) 0.51
  Sociocultural 1176 (100) 506 (100) 670 (100) –
   Lack of caregiver support 1176 (100) 506 (100) 670 (100) –
   Belief conflict 1 (0.1) 0 (0.0) 1 (0.1) 0.57
   Language barriers 1 (0.1) 1 (0.2) 0 (0.0) 0.43
   Social exclusion 1 (0.1) 0 (0.0) 1 (0.1) 1
  CCIF, median (IQR) 4 (3–6) 5 (4–6) 4 (3–5) <0.001
*Unfavourable outcomes included in- hospital mortality and adverse events during hospitalisation
†VIDA score was analysed according to 806 patients admitted to wards using the VIDA system.
APR- DRG, All Patient Refined Diagnosis- Related Group; ICU, intensive care unit; IQR, interquartile range; LOS, length of hospital stay; VIDA, Surveillance and 
Identification of Acute Deterioration.
Table 1 Continued
Table 2 Patient outcomes according to risk of acute deterioration (VIDA score) and care complexity factors
Outcomes
  
VIDA score n=806 (68.5) CCIF n=1176
All Low risk (0) Mild risk (1–2) High risk (3–4) CCIF<4 CCIF≥4
n=1176 n=104 (12.9) n=505 (62.7) n=197 (16.7) n=327 (27.8) n=849 (72.2)
n (%) n (%) n (%) n (%) n (%) n (%)
Unfavourable outcomes 506 (43.0) 27 (26.0)** 194 (38.4)* 158 (80.2)** 92 (28.1)** 414 (48.8)**
  Deceased 232 (19.6) 0 (0.0)** 46 (9.1)** 118 (59.9)** 5 (1.5)** 227 (26.7)**
  Adverse event 481 (40.9) 27 (26.0)** 187 (37)* 153 (77.7)** 91 (27.8)** 394 (46.4)**
  ICU transfer 32 (2.7) 0 (0.0)* 12 (2.4) 13 (6.6)* 4 (1.2)* 28 (3.3)*
  HAI 29 (2.5) 0 (0.0)* 10 (2) 12 (6.1)* 1 (1.5) 24 (2.8)
    Catheter- related bloodstream 
infection
1 (0.1) 0 (0) 0 (0) 1 (0.5) 0 (0) 1 (0.1)
    Hospital acquired urinary tract 
infection
19 (1.6) 0 (0) 7 (1.4) 8 (4.1)* 3 (0.9) 16 (1.9)
   Aspiration pneumonia 3 (0.3) 0 (0) 3 (0.6) 0 (0) 0 (0) 3 (0.4)
   Sepsis 7 (0.6) 0 (0) 10.2 3 (1.5)* 2 (0.6) 5 (0.6)
  ACC 470 (40) 27 (26.0)** 181 (35.8)** 150 (76.1)** 88 (26.6)** 383 (45.1)**
   Cardiac arrest 5 (0.4) 1 (1) 0 (0.0)* 3 (1.5)* 0 (0) 5 (0.6)
   Shock 4 (0.3) 0 (0) 2 (0.4) 0 (0) 0 (0) 4 (0.5)
   Thrombotic event 7 (0.6) 1 (1) 1 (0.2) 2 (1) 1 (0.3) 6 (0.7)
   Acute respiratory failure† 436 (37) 27 (26.0)** 164 (32.5)** 144 (73.1)** 84 (25.1)** 353 (41.6)**
   Myocardial injury 5 (0.4) 0 (0) 3 (0.6) 1 (0.5) 0 (0) 5 (0.6)
   Liver injury 2 (0.2) 0 (0) 0 (0) 1 (0.5) 0 (0) 2 (0.2)
   Renal insufficiency 83 (7.1) 1 (1.0)* 28 (5.5)* 31 (15.7)** 6 (1.8)** 77 (9.1)**
*P>0.001 and p<0.05; **p≤0.001.
†Includes acute respiratory distress syndrome (ARDS).
ACC, avoidable critical complications; CCIF, care complexity individual factors; HAI, hospital- acquired infections; ICU, intensive care unit; VIDA, Surveillance and 
Identification of Acute Deterioration.
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In- hospital mortality was more frequent in patients 
admitted to wards where registered nurses (RN) were not 
using the VIDA early warning system. In this regard, other 
studies have shown that the use of early warning systems 
reinforces collaboration among the multidisciplinary 
team, and promotes the early identification of clinical 
deterioration.24 Similarly, previous studies have reported 
lower mortality and fewer AEs when systematic nursing 
surveillance of patient status and progress is part of the 
daily routine.9
Chronic conditions and mental status impairments 
were the CCIFs independently associated with unfavour-
able outcomes. Previous reports have shown that chronic 
diseases were more frequent among deceased patients 
with COVID-1915 and that ageing was a potential risk 
factor associated with mortality.6 Although our study did 
not identify age as a risk factor associated with a composite 
unfavourable outcome, we acknowledge that old age was 
an independent risk factor associated with mortality and 
AEs. Furthermore, our findings are also consistent with 
other studies demonstrating that mental status impair-
ment is associated with hospital- acquired complications,25 
including sepsis.4
The majority of patients had four or more CCIFs. Our 
findings are consistent with other studies that identified 
a significant rate of chronic conditions in patients with 
COVID-1915 along with various organisational issues that 
may impact care complexity and health outcomes.26 
Previous studies have demonstrated the association of 
CCIF and health outcomes,16 with an average of two 
CCIFs per patient. In our study of COVID-19 inpatients, 
the average number of CCIFs was 4. These results are 
Table 3 Adjusted analysis of unfavourable outcomes according to VIDA early warning system in 486 patients with high risk of 
mortality (APR- DRG 3–4)
Outcomes
Unadjusted Adjusted With VIDA system Without VIDA system
P value*
n=1176 n=486 (41.2) n=368 (75.7) n=118 (24.3)
n (%) n (%) n (%) n (%)
Unfavourable outcomes 506 (43) 449 (92.4) 345 (93.8) 104 (88.1) 0.07
  Deceased 232 (19.6) 214 (44) 152 (41.3) 62 (52.5) 0.02
  Adverse event 481 (40.9) 436 (89.7) 337 (91.6) 99 (83.9) 0.02
  ICU transfer 32 (2.7) 25 (5.1) 20 (5.4) 5 (4.2) 0.41
  HAI 29 (2.5) 19 (3.9) 16 (4.3) 3 (2.5) 0.28
  ACC 470 (40) 433 (89.1) 334 (90.8) 99 (83.9) 0.31
*All variables were compared using the Fisher’s exact test.
ACC, avoidable critical complications; APR- DRG, All Patient Refined Diagnosis- Related Group; HAI, hospital- acquired infections; ICU, intensive care 
unit; VIDA, Surveillance and Identification of Acute Deterioration.
Table 4 Multivariate analysis of VIDA score and CCIF in 806 adult COVID-19 inpatients associated with unfavourable 
outcomes, death and AEs
Characteristics
Unfavourable outcomes† Deceased‡ AEs§
n=379/806 (47%) n=164/806 (20.3%) n=367/806 (45.5%)
OR (95% CI) OR (95% CI) OR (95% CI)
Old age (≥75 years) 1.48 (0.99 to 2.22) 3.04 (1.79 to 5.15)** 1.52 (1.02 to 2.26)*
Male sex 1.21 (0.87 to 1.69) 1.86 (1.11 to 3.11)* 1.2 (0.87 to 1.67)
LOS 1.16 (1.11 to 1.21)** 0.97 (0.93 to 1.01) 1.17 (1.12 to 1.22)**
High- tech hospital 0.57 (0.36 to 0.89)* 1.88 (0.94 to 3.78) 0.61 (0.39 to 0.95)*
VIDA score 3–4 4.32 (2.83 to 6.60)** 13.99 (8.44 to 23.18)** 4.21 (2.79 to 6.36)**
Chronic disease 1.9 (1.32 to 2.72)** 2.01 (1.03 to 3.90)* 1.81 (1.26 to 2.59)**
Position impairment 1.19 (0.58 to 2.44) 1.41 (0.63 to 3.13) 1.23 (0.62 to 2.46)
Communication disorders 0.97 (0.24 to 3.96) 0.87 (0.22 to 3.41) 0.78 (0.21 to 2.95)
Mental status impairments 2.31 (1.45 to 23.66)** 6.21 (3.67 to 10.50)** 1.72 (1.09 to 2.69)*
Multivariate analysis included: high risk of acute deterioration (VIDA score 3–4), clinically relevant care complexity factors (old age, chronic disease, 
position impairment, communication disorders and mental status impairments) and potential confounders (sex, hospital level and LOS).
*P>0.001 and p<0.05; **p≤0.001.
†AUC 0.81 (95% CI 0.78 to 0.84).
‡AUC 0.91 (95% CI 0.88 to 0.93).
§AUC 0.80 (95% CI 0.77 to 0.83).
AE, adverse event; AUC, area under the receiver operating characteristic curve; CCIF, care complexity individual factors; CI, Confidence interval; 
LOS, length of hospital stay; OR, Odds ratio; VIDA, Surveillance and Identification of Acute Deterioration.
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probably related to the transmissibility of this condition, 
which requires droplet and contact precautions; the 
public health measures of population confinement for 
pandemic management, which prevent patients’ rela-
tives from visiting them in person, resulting in a lack of 
family caregiver support during hospitalisation; and the 
frequency of chronic diseases in the studied sample. The 
organisational adaptation of hospitals to this pandemic 
context and the required isolation precautions have been 
associated with poor outcomes in prior studies.27 28
We also found that LOS was associated with unfavour-
able outcomes, consistent with previous studies that asso-
ciated AEs with increased healthcare costs due to longer 
hospital stays.29 Finally, high- tech hospital admission was 
a protective factor against unfavourable outcomes. High- 
tech hospitals usually have better nurse to patient ratios 
than urban or community facilities. In this sense, several 
recent studies in the same study setting concluded that 
on average, hospital ward patients require 5.6 hours of 
RN care per patient- day, while the average of available RN 
hours per patient- day is 2.4, and that RN understaffing 
is a structural issue.26 30 Nevertheless, to the best of our 
knowledge, no study on nurse staffing and COVID-19 
inpatient outcomes has been published. Similarly, clinical 
leaders and healthcare managers have a key role to play 
in rapidly adapting organisations to the new reality. Fast 
and effective decision- making and managerial responses 
in crisis situations with high levels of uncertainty are 
essential both immediately and in the short term; 
however, they should be accompanied by planning and 
executing mid- term and long- lasting improvements that 
positively impact patient, professional and organisational 
outcomes, such as structural RN understaffing.26
The strengths of this study include its multicentre 
approach, cohort design and large sample size. It is the 
first study evaluating the association of the risk of acute 
deterioration, along with care complexity factors, with 
outcomes of patients with COVID-19. Importantly, we 
identify the importance of a range of contributors to care 
complexity, including psychosocial and mental- cognitive 
factors. In addition, the VIDA early warning system was 
developed as an evidence- based algorithm using a multi-
disciplinary approach, based on previous studies that 
highlighted the importance of adapting surveillance 
and screening systems to the organisational and cultural 
context.14
This study is not exempt from limitations. First, 
the VIDA score and CCIF data were comprehensively 
collected from the clinical data warehouse of the 
Catalan Institute of Health and all patients included 
had a completed nurse chart in the patient electronic 
health record, but we were still reliant on proper 
compliance with electronic record keeping and the 
collection of administrative data. This is acknowledged 
as a significant limitation since voluntary completion 
of patient electronic documentation during the initial 
weeks of the first wave of COVID-19 in our country 
might have been negatively influenced by the rising 
hospital burden, the understandable prioritisation 
of direct patient care, as well as the physical and 
emotional stress experienced by bedside healthcare 
professionals. Second, regarding the study selection 
criteria, patients directly admitted and discharged 
from the ICU were excluded, since no early warning 
system was in use in the critical care setting at the 
outset of the pandemic in our study area. In this sense, 
the results of this study only apply to adult ward and 
intermediate care inpatients. Third, it should be noted 
that of the 1176 patients included, only 806 were 
hospitalised in wards with a fully implemented VIDA 
system. Therefore, patients admitted to wards without 
the VIDA system did not have data available on risk 
of acute deterioration (VIDA score). This is a signifi-
cant limitation. The VIDA system was under develop-
ment in hospitals belonging to the Catalan Institute of 
Health during the data collection period. Therefore, 
future studies should corroborate the current results 
in centres where VIDA has been fully implemented. 
However, due to the high number of daily admissions, 
the patients’ unplanned assignment to the different 
wards (with or without the VIDA system) means that 
the patients’ clinical characteristics were similar 
between wards with and without the VIDA system. 
Fourth, although an unpublished face validity study 
has demonstrated the effectiveness of the VIDA early 
warning system, full evaluation of its psychometric 
properties is still pending. To minimise the potential 
effect of this limitation, we conducted an adjusted 
analysis performed with 486 patients with a similar 
higher risk of mortality (APR- DRG 3–4), comparing 
those admitted to wards using VIDA with those being 
treated in units with no VIDA early warning system. 
The results show that in- hospital mortality was more 
frequent in patients admitted to wards where VIDA had 
not yet been implemented. This result should be inter-
preted with caution because this analysis only included 
patients with a high risk of mortality and could have 
been influenced by other variables such as the differ-
ences in sample sizes. Finally, we acknowledge as a 
potential limitation that other clinical measures such 
as the age- adjusted Charlson Comorbidity Index or 
patient laboratory values were not assessed. Selected 
laboratory values such as lactate, ferritin or calciferol 
have been studied as indicators of COVID-19 prog-
nosis and severity. Combining point- of- care labora-
tory data with clinical data from nurses’ observations 
and judgements on patient complexity factors, status 
and progress would probably result in an improved 
system for the early detection and prevention of crit-
ical complications and other unfavourable outcomes 
in COVID-19 inpatients.
CONCLUSION
The risk of acute deterioration and CCIF is associated 
with outcomes of patients with COVID-19. The rate 
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of unfavourable outcomes rose with increasing risk of 
acute deterioration as measured using the VIDA score. 
The risk factors independently associated with poor 
health outcomes were chronic disease, mental status 
impairment, LOS and high risk of acute deterioration. 
High- tech hospital admission was a protective factor 
against unfavourable outcomes. The systematic nursing 
surveillance of patients at risk of acute deterioration 
and the assessment of CCIF may help reduce delete-
rious health outcomes in adult COVID-19 inpatients.
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